A high dose of Novo Nordisk’s obesity drug Wegovy led patients to lose substantial weight in a clinical trial, but still less ...

Biopharma executives shared their thoughts on the potential impacts of the new administration; Annalee Armstrong recaps JPM ...

GLP-1 medications linked to a lower risk of dementia and addiction but higher risk of kidney, pancreatic, and ...

For one, Lilly in early December shared the results of a head-to-head trial pitting Zepbound against Wegovy, in which Zepbound emerged triumphant. According to the study, participants taking ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market in a decade. After a fallow period ...

This time last year, people were still bickering about whether Novo Nordisk’s Wegovy and Eli Lilly & Co.’s Zepbound represented a shortcut to losing weight or a medical breakthrough.

There’s still scope for a new generation of drugs to replace weight-loss market leaders like Novo Nordisk A/S’s Wegovy, according to the chief executive officer of Zealand Pharma A/S ...

It opens the door for broader coverage and access to Zepbound, which is not currently covered by Medicare and many other insurance plans for weight loss.

“Zepbound’s superior efficacy and strategic market expansion suggest that the drug will dominate the obesity market, surpassing Novo Nordisk's Wegovy (semaglutide),” GlobalData said in a ...

Medicare will seek to negotiate lower list prices for the blockbuster diabetes and weight loss drugs Ozempic and Wegovy and 14 other ... and weight loss drug Zepbound because they haven't been ...

According to leading data and analytics company GlobalData, Eli Lilly’s Zepbound (tirzepatide) is poised to surpass Novo Nordisk’s Wegovy (semaglutide), despite expectations for continued ...

‘#Obesity Market Shift? #Eli_Lilly's #Zepbound could overtake #Novo_Nordisk's #Wegovy as the dominant player.’ “From the start, Zepbound emerged as the primary new competitor of ...